
06.27.2025
Where science meetssoftware.
Click Therapeutics is redefining modern medicine with patient-centric digital treatments. Operating at the intersection of biology and technology, Click combines neuroscience with the power of software, creating a new way to treat disease.
We develop, validate, and commercialize software as prescription medical treatments for people with unmet medical needs.
Click SE™ solutions combine software with pharmacotherapy to create software-enhanced drug™ treatments, designed to deliver added clinical benefit to patients compared to drug alone.
Our multimodal, platform-based approach targets disease and drives outcomes from multiple different angles, combining scientifically proven therapies with proprietary neuromodulatory mechanisms of action to deliver clinically-meaningful interventions.
Collaborators
Contact
Speaker:
David Benshoof Klein
Founder & CEO
Fierce Pharma Virtual Webinar
Click Therapeutics is pleased to announce FDA marketing authorization for CT-132, the first prescription digital therapeutic for the preventive treatment of episodic migraine in the United States. FDA marketing authorization for CT-132 is supported by data from both the pivotal ReMMi-D randomized controlled trial, in which CT-132 met its primary endpoint by significantly reducing monthly migraine days on top of background pharmacotherapy, and the bridging study, ReMMiD-C, where CT-132 showed similar performance in patients on calcitonin gene-related peptide (CGRP) inhibitors.
CT-132 combines scientifically proven therapies with proprietary mechanisms of action to deliver clinically-meaningful interventions for patients with episodic migraine. Intended for adjunctive use alongside other treatments for migraine, CT-132 demonstrated in clinical testing the ability to add clinically meaningful benefit on top of background pharmacotherapy.
Speaker:
David Benshoof Klein
Founder & CEO
Fierce Pharma Virtual Webinar
Click Therapeutics is pleased to announce FDA marketing authorization for CT-132, the first prescription digital therapeutic for the preventive treatment of episodic migraine in the United States. FDA marketing authorization for CT-132 is supported by data from both the pivotal ReMMi-D randomized controlled trial, in which CT-132 met its primary endpoint by significantly reducing monthly migraine days on top of background pharmacotherapy, and the bridging study, ReMMiD-C, where CT-132 showed similar performance in patients on calcitonin gene-related peptide (CGRP) inhibitors.
CT-132 combines scientifically proven therapies with proprietary mechanisms of action to deliver clinically-meaningful interventions for patients with episodic migraine. Intended for adjunctive use alongside other treatments for migraine, CT-132 demonstrated in clinical testing the ability to add clinically meaningful benefit on top of background pharmacotherapy.